[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

901.O2.6 901. Health Services and Outcomes Research: Health Services Research in Malignant Hematological Disorders

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 10:30 AM-12:00 PM
Elizabeth Ballroom FG (Manchester Grand Hyatt San Diego)
Moderators:
Smita Bhatia, MD, MPH, City of Hope and K. Scott Baker, MD, MS, Fred Hutchinson Cancer Research Ctr.

Disclosures:
No relevant conflicts of interest to declare.
10:30 AM
Medicare Fee-for-Service Enrollees with Acute Myelogenous Leukemia: An Analysis of Treatment Patterns and Patient Survival

Juliana Leah Meyers, MA1*, Yanni F Yu2* and Keith L Davis1*

1Health Economics, RTI Health Solutions, Research Triangle Park, NC
2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

10:45 AM
The Limited Screening Value of Insulin-Like Growth Factor-I in 610 Very Long Term Adult Survivors of Leukemia and Other Types of Childhood CancerClinically Relevant Abstract

Karin Blijdorp1*, Marry M. van den Heuvel, MD, PhD2*, Rob Pieters, MD, PhD3, Annemieke Boot4*, Aartjan van der Lely5* and Sebastian J.C.M.M. Neggers, MD, PhD6*

1Pediatric Oncology, Erasmus University, Rotterdam, Netherlands
2Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
3Dept. of Pediatric Hematology/Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
4Pediatric endocrinology, Academic Medical Centre Groningen (UMCG)
5Internal Medicine, Erasmus MC–University Medical Center Rotterdam
6Department of Medicine, section Endocrinology, Erasmus University Medical Center , Rotterdam, Netherlands

11:00 AM
Hiatus in Infant Acute Leukemia Incidence rates in Belarus: Adaptation-to-Low-Dose-Radiation Phenomenon?

Vadim Ivanov, MD, PhD1, Tatiana Terehovich, MD, PhD2* and Eugene Ivanov, MD, PhD3*

1Hematology, Institut Paoli-Calmettes, Marseille, France
2Republican Scientific and Practical Centre of Medical Technologies, Minsk
3Department of Radiochemistry, Belarussian State University, Minsk, Belarus

11:15 AM
Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

Benjamin Djulbegovic, MD, PhD1, Ambuj Kumar, MD, MPH2, Branko Miladinovic, PhD3*, Asmita Mhaskar, MPH4*, Tea Reljic, BS3*, Sanja Galeb, BS5*, Rahul Mhaskar, MPH, PhD4*, Hozo Iztok, PhD6*, Dongsheng Tu7*, Heather Stanton7*, Christopher M Booth7* and Ralph M. Meyer, MD7

1Center for evidence based medicine and health outcomes research, University of South Florida , Tampa, FL
2University of South Florida, College of Medicine, Center for Evidence Based Medicine, Tampa
3Center for Evidence-based Medicine , University of South Florida , Tampa, FL
4Center for Evidence-Based Medicine, University of South Florida, Tampa, FL
5Moffitt Cancer Center, Tampa, FL
6Indiana University Northwest, gary, IN
7NCIC CTG, Kingston, Canada

11:30 AM
Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies

Benny Kusuma, MD1* and Ronald S. Go, MD2

1Internal Medicine, Gundersen Lutheran Health System, La Crosse, WI
2Center for Cancer and Blood Disorders, Gundersen Lutheran Health System, La Crosse, WI

11:45 AM
Increased Cytogenetic Testing and Prognostic Assessment Do Not Translate Into Higher Active Treatment of Elderly MDS Patients in GermanyClinically Relevant Abstract

Norbert Gattermann, MD1, Andrea Kuendgen, MD2*, Lenka Kellermann, BS, MBA3*, Matti Zeffel, BS4*, Bernadette Paessens, PhD5* and Ulrich Germing, MD6*

1Heinrich-Heine-Universitat, Düsseldorf, Germany
2Heinrich-Heine University of Düsseldorf, Duesseldorf, Germany
3OncologyInformationService, Freiburg, Germany
4Market Research, Celgene GmbH, Munich, Germany
5Medical Communications, Celgene GmbH, D-81829 Munich, Germany
6Hematology, University Hospital Düsseldorf, Düsseldorf, Germany

*signifies non-member of ASH